Stuttgart - Delayed Quote EUR

Amphastar Pharmaceuticals Inc (29A.SG)

34.66

-0.05

(-0.14%)

As of 8:00:44 AM GMT+1. Market Open.

Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on ...

ACCESSWIRE 2 days ago

AMPH
Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Simply Wall St. last month

AMPH
Implied Volatility Surging for Amphastar Pharmceuticals (AMPH) Stock Options

Investors need to pay close attention to Amphastar Pharmceuticals (AMPH) stock based on the movements in the options market lately.

Zacks last month

AMPH
Why Amphastar Pharmaceuticals (AMPH) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against the other most profitable pharmaceutical stocks. The Pharmaceutical Industry: Growth, Innovation, and Emerging Challenges Healthcare, which includes numerous businesses that offer patient care, conduct […]

Insider Monkey last month

AMPH
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, ...

ACCESSWIRE last month

AMPH
Amphastar initiated with an Equal Weight at Wells Fargo

Wells Fargo initiated coverage of Amphastar (AMPH) with an Equal Weight rating and $55 price target The firm likes the setup heading into 2025, saying Amphastar could have 2-3 new launches over the next 12 months, “yet is trading as if there is no pipeline.” Amphastar has a solid commercial business and just a few pipeline wins could drive long-term growth, the analyst tells investors in a research note. Wells sees 20% upside in the shares as the company enters a new product cycle. Published fir

TipRanks last month

AMPH
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside ...

ACCESSWIRE last month

AMPH
Amphastar Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

Amphastar Pharmaceuticals ( NASDAQ:AMPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$191.2m (up 5.9...

Simply Wall St. 2 months ago

AMPH
Q3 2024 Amphastar Pharmaceuticals Inc Earnings Call

Q3 2024 Amphastar Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

AMPH

LLY
Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Call Highlights: Resilient Revenue Growth ...

Amphastar Pharmaceuticals Inc (AMPH) reports a 6% revenue increase, driven by record Primatene Mist sales, despite facing competitive and logistical hurdles.

GuruFocus.com 2 months ago

AMPH
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 2 months ago

AMPH
Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of -4.95% and 2.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AMPH
Amphastar: Q3 Earnings Snapshot

AMPH) on Wednesday reported third-quarter net income of $40.4 million. The Rancho Cucamonga, California-based company said it had net income of 78 cents per share. Earnings, adjusted for one-time gains and costs, came to 96 cents per share.

Associated Press Finance 2 months ago

AMPH
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024

Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the ...

ACCESSWIRE 2 months ago

AMPH
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

BBIO

AMPH
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

AMPH
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November ...

ACCESSWIRE 2 months ago

AMPH
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 2 months ago

AMPH
Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 2 months ago

AMPH
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Is Going Strong: Is the Market Following Fundamentals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has had a great run on the share market with its stock up by a significant 25...

Simply Wall St. 2 months ago

AMPH

Performance Overview

Return	29A.SG	S&P 500
YTD	-1.87%	+0.19%
1-Year	-33.98%	+24.42%
3-Year	+66.63%	+26.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amphastar Pharmaceuticals Inc (29A.SG)

Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?

Implied Volatility Surging for Amphastar Pharmceuticals (AMPH) Stock Options

Why Amphastar Pharmaceuticals (AMPH) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

Amphastar initiated with an Equal Weight at Wells Fargo

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Amphastar Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

Q3 2024 Amphastar Pharmaceuticals Inc Earnings Call

Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Call Highlights: Resilient Revenue Growth ...

Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings

Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates

Amphastar: Q3 Earnings Snapshot

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Is Going Strong: Is the Market Following Fundamentals?

Performance Overview